News
PLRX
11.81
-0.59%
-0.07
Weekly Report: what happened at PLRX last week (0415-0419)?
Weekly Report · 4d ago
Weekly Report: what happened at PLRX last week (0408-0412)?
Weekly Report · 04/15 09:03
Pliant Therapeutics Poised for Growth: A Strong Buy on Promising Drug Pipeline and Strategic Leadership
TipRanks · 04/10 10:45
Weekly Report: what happened at PLRX last week (0401-0405)?
Weekly Report · 04/08 09:03
Weekly Report: what happened at PLRX last week (0325-0329)?
Weekly Report · 04/01 09:03
Weekly Report: what happened at PLRX last week (0318-0322)?
Weekly Report · 03/25 09:03
MASI, PLRX and CGC are among after hour movers
On the Move MASI, PLRX and CGC are among after hour movers. Airship AI Holdings and AISP are among the losers in the tech sector. The day's top 10 stocks include CAMP, CGNX and MLCO.
Seeking Alpha · 03/22 20:59
Weekly Report: what happened at PLRX last week (0311-0315)?
Weekly Report · 03/18 09:03
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Bioventus (BVS) and Pliant Therapeutics (PLRX)
3 analysts maintain Buy ratings on BioMarin Pharmaceutical (BMRN), Bioventus (BVS) and Pliant Therapeutics (PLRX) 3 analysts have just weighed in on the Healthcare sector with bullish sentiments for the 3 stocks.
TipRanks · 03/13 11:11
Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO) and Pliant Therapeutics (PLRX)
TipRanks · 03/12 16:50
Pliant Therapeutics Price Target Maintained With a $38.00/Share by Needham
Dow Jones · 03/12 16:49
Needham Reiterates Buy on Pliant Therapeutics, Maintains $38 Price Target
Benzinga · 03/12 16:40
Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis
Pliant Therapeutics, Inc. Announces implementation of BEACON-IPF as a pivotal, adaptive Phase 2b/3 trial in patients with idiopathic pulmonary fibrosis. Bexotegrast is an oral, small molecule in clinical development for the treatment of IPF.
Benzinga · 03/12 11:35
Weekly Report: what happened at PLRX last week (0304-0308)?
Weekly Report · 03/11 09:03
Pliant Therapeutics: Strong Buy Rating on Promising Pipeline and Solid Financials
TipRanks · 03/08 12:56
Pliant Therapeutics Price Target Raised to $54.00/Share From $50.00 by RBC Capital
Dow Jones · 03/05 15:37
Pliant Therapeutics Is Maintained at Outperform by RBC Capital
Dow Jones · 03/05 15:37
RBC Capital Maintains Outperform on Pliant Therapeutics, Raises Price Target to $54
Benzinga · 03/05 15:32
Weekly Report: what happened at PLRX last week (0226-0301)?
Weekly Report · 03/04 09:03
Maintaining Buy Rating on Pliant Therapeutics: Promising Clinical Advances and Solid Financial Footing
TipRanks · 03/01 06:00
More
Webull provides a variety of real-time PLRX stock news. You can receive the latest news about Pliant Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About PLRX
Pliant Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing therapies for the treatment of fibrosis and related diseases. Its lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). The Company has initiated BEACON-IPF, a Phase 2b trial of bexotegrast in IPF. It has also developed PLN-1474, a small molecule, selective inhibitor of αvß1 integrin for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis. It has initiated a Phase 1 study for its third clinical program, PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being developed for the treatment of solid tumors. The Company has a preclinical program, PLN-101325, targeting muscular dystrophies.